1. Home
  2. PBYI vs JYNT Comparison

PBYI vs JYNT Comparison

Compare PBYI & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • JYNT
  • Stock Information
  • Founded
  • PBYI 2010
  • JYNT 2010
  • Country
  • PBYI United States
  • JYNT United States
  • Employees
  • PBYI N/A
  • JYNT N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • JYNT Multi-Sector Companies
  • Sector
  • PBYI Health Care
  • JYNT Miscellaneous
  • Exchange
  • PBYI Nasdaq
  • JYNT Nasdaq
  • Market Cap
  • PBYI 164.3M
  • JYNT 170.1M
  • IPO Year
  • PBYI N/A
  • JYNT 2014
  • Fundamental
  • Price
  • PBYI $3.45
  • JYNT $11.60
  • Analyst Decision
  • PBYI Strong Buy
  • JYNT Strong Buy
  • Analyst Count
  • PBYI 1
  • JYNT 2
  • Target Price
  • PBYI $7.00
  • JYNT $15.50
  • AVG Volume (30 Days)
  • PBYI 307.3K
  • JYNT 73.1K
  • Earning Date
  • PBYI 07-31-2025
  • JYNT 08-07-2025
  • Dividend Yield
  • PBYI N/A
  • JYNT N/A
  • EPS Growth
  • PBYI 143.51
  • JYNT N/A
  • EPS
  • PBYI 0.77
  • JYNT N/A
  • Revenue
  • PBYI $232,709,000.00
  • JYNT $52,789,479.00
  • Revenue This Year
  • PBYI N/A
  • JYNT $9.72
  • Revenue Next Year
  • PBYI N/A
  • JYNT $10.92
  • P/E Ratio
  • PBYI $4.43
  • JYNT N/A
  • Revenue Growth
  • PBYI 2.68
  • JYNT 71.05
  • 52 Week Low
  • PBYI $2.23
  • JYNT $9.58
  • 52 Week High
  • PBYI $4.13
  • JYNT $15.32
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 50.12
  • JYNT 54.97
  • Support Level
  • PBYI $3.26
  • JYNT $11.71
  • Resistance Level
  • PBYI $3.68
  • JYNT $12.27
  • Average True Range (ATR)
  • PBYI 0.12
  • JYNT 0.62
  • MACD
  • PBYI 0.00
  • JYNT -0.01
  • Stochastic Oscillator
  • PBYI 52.90
  • JYNT 46.05

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.

Share on Social Networks: